SERPINA11 Antibody

What is SERPINA11 and why is it relevant for research?

SERPINA11 is a member of the serpin family of protease inhibitors with serine-type endopeptidase inhibitory activity. Research has revealed its potential role as a tumor suppressor in hepatocellular carcinoma, where it is frequently downregulated in tumor tissues compared to normal liver tissue . More recently, a biallelic loss of function variant in SERPINA11 has been associated with a perinatal lethal phenotype characterized by extracellular matrix disruption, suggesting its critical role in embryonic development . SERPINA11 appears to regulate proteolysis and maintain extracellular matrix homeostasis by inhibiting tissue serine proteases. Its expression pattern spans multiple tissues, making it relevant for research across various physiological systems.

Which techniques can be used to detect SERPINA11 protein expression?

Multiple techniques have been validated for detecting SERPINA11 protein expression:

• Western blot (WB): Effective for quantifying expression levels and confirming molecular weight (approximately 47 kDa)

• Immunohistochemistry (IHC): Useful for tissue localization studies

• Immunofluorescence: Particularly valuable for co-localization studies with other proteins

• ELISA: Appropriate for quantitative measurement of SERPINA11 in biological fluids and cell culture supernatants

For optimal results, researchers should consider tissue-specific expression patterns and potential post-translational modifications, as differential glycosylation of SERPINA11 has been observed across tissues, resulting in varying molecular weights .

In which tissues is SERPINA11 protein predominantly expressed?

Research has demonstrated SERPINA11 expression across multiple tissues:

While SERPINA11 transcript has been traditionally reported predominantly in the liver, protein detection in multiple tissues suggests either transport via circulation or low-level transcription in these tissues . Additionally, expression appears to be important during embryonic development, with detection in multiple fetal tissues.

What are the optimal conditions for using SERPINA11 antibodies in Western blot analysis?

For Western blot detection of SERPINA11, researchers should consider the following protocol parameters:

• Sample preparation: Use tissue lysates or cell lines known to express SERPINA11 (HepG2, HT-29, MCF-7, Raji)

• Protein loading: 4-10 μg of total protein is typically sufficient

• Gel percentage: 12% polyacrylamide gels provide good resolution for the 47 kDa SERPINA11 protein

• Transfer conditions: 1.5 hours at 390 mA to nitrocellulose membrane

• Blocking: 5% non-fat milk or 5% ECL blocking agent in PBS with 0.1% Tween-20 (PBST)

• Primary antibody dilution: 1:500-1:5000 for polyclonal antibodies; specific recommendations may vary by product

• Incubation conditions: Overnight at 4°C for optimal signal-to-noise ratio

• Secondary antibody: Anti-rabbit IgG-HRP (typically 1:5000-1:50000 dilution)

• Expected molecular weight: The predicted molecular weight is 47 kDa, but tissue-specific glycosylation may result in bands of higher molecular weight

Researchers should be aware that SERPINA11 may display different molecular weights in different tissues due to post-translational modifications, particularly glycosylation .

How should SERPINA11 antibodies be validated for specificity?

Thorough validation of SERPINA11 antibodies is critical for research reproducibility. Recommended validation approaches include:

• Positive controls: Test antibodies against recombinant SERPINA11 protein or lysates from tissues/cell lines with known expression (liver, HepG2 cells)

• Multiple detection methods: Confirm results using orthogonal methods (WB, IHC, immunofluorescence)

• Peptide blocking: Pre-incubate antibody with immunizing peptide to confirm specificity of binding

• Knockdown/knockout controls: Validate using tissues or cells from SERPINA11 knockdown/knockout models, which should show reduced or absent signal

• Cross-reactivity testing: Test against closely related serpins to ensure specificity

• Multiple antibodies targeting different epitopes: When possible, confirm results using antibodies recognizing different regions of SERPINA11

For example, antibodies targeting different epitopes along the SERPINA11 protein (peptide #1 (aa 16–30), peptide #2 (aa 140–154), peptide #3 (aa 268–279), peptide #4 (aa 191–209), and peptide #5 (aa 340–368)) can provide complementary information about protein expression and processing .

What controls should be included when performing immunohistochemistry with SERPINA11 antibodies?

For rigorous immunohistochemical analysis of SERPINA11, researchers should include:

• Positive tissue controls: Human liver and lung tissues are recommended as they show consistent SERPINA11 expression

• Negative tissue controls: Tissues known to lack SERPINA11 expression

• Antibody controls:

  • Primary antibody omission control

  • Isotype control (e.g., rabbit IgG for rabbit-derived antibodies)

  • Peptide competition control (pre-incubation with immunizing peptide)

• Signal specificity controls:

  • Sequential dilutions of primary antibody to determine optimal concentration

  • Comparative staining with different antibodies targeting SERPINA11

For antigen retrieval, Tris-EDTA buffer (pH 9.0) with high-pressure cooking for 4 minutes has been successfully employed . The recommended antibody dilution for IHC ranges from 1:50-1:300, with overnight incubation at 4°C .

How can SERPINA11 antibodies be used to investigate its role in hepatocellular carcinoma?

SERPINA11 has been identified as a potential tumor suppressor in hepatocellular carcinoma (HCC), with downregulation observed in approximately 48.4% of HCC tissues compared to adjacent non-tumor tissue . Researchers investigating this relationship can employ SERPINA11 antibodies in the following approaches:

• Expression profiling: Compare SERPINA11 protein levels between HCC and paired normal tissues using Western blot and IHC

• Prognostic correlation: Analyze the relationship between SERPINA11 expression and clinical outcomes using tissue microarrays and survival analysis

• Mechanistic studies:

  • Investigate SERPINA11 interaction with urokinase-type plasminogen activator (uPA) through co-immunoprecipitation

  • Examine downstream signaling pathways including MEK/ERK using phospho-specific antibodies alongside SERPINA11 detection

• Functional validation: In cells with SERPINA11 overexpression or knockdown, monitor invasion and metastasis-related phenotypes alongside protein expression

• Secretome analysis: Quantify secreted SERPINA11 in cell culture supernatants using ELISA to assess its extracellular function

Research has shown that SERPINA11 may inhibit HCC metastasis by inhibiting uPA activity and subsequently modulating the MEK/ERK signaling pathway, providing specific molecular mechanisms to investigate .

What experimental approaches can reveal SERPINA11's role in extracellular matrix regulation?

Recent research has implicated SERPINA11 in extracellular matrix homeostasis, with biallelic loss-of-function variants causing perinatal lethality characterized by extracellular matrix disruption . To investigate this function, researchers can employ these approaches:

• Histological analysis: Compare extracellular matrix organization in tissues with varied SERPINA11 expression using specialized stains (Masson's trichrome, picrosirius red) alongside SERPINA11 immunostaining

• Protease activity assays: Measure the activity of potential target proteases (e.g., matrix metalloproteinases, serine proteases) in models with altered SERPINA11 expression

• Biochemical interaction studies:

  • Co-immunoprecipitation to identify protease binding partners

  • In vitro inhibition assays to determine stoichiometry of inhibition for candidate proteases

• Developmental biology approaches: Study the temporal and spatial expression of SERPINA11 during embryonic development using immunofluorescence

• Cell culture models: Examine extracellular matrix production and turnover in cells with SERPINA11 overexpression or knockdown

When designing such experiments, researchers should consider the potential role of SERPINA11's reactive center loop (RCL, residues 366-397), which is critical for protease inhibition and is absent in truncated variants associated with disease .

How can researchers investigate potential post-translational modifications of SERPINA11?

SERPINA11 appears to undergo significant post-translational modifications, particularly N-linked glycosylation, which may vary across tissues . To characterize these modifications:

• Glycosylation analysis:

  • Compare apparent molecular weights across tissues by Western blot

  • Treat samples with glycosidases (PNGase F, Endo H) prior to Western blot to remove N-linked glycans

  • Use lectins alongside SERPINA11 antibodies to characterize glycan structures

• Mass spectrometry:

  • Immunoprecipitate SERPINA11 from different tissues

  • Perform mass spectrometry to identify specific modifications and their attachment sites

• Site-directed mutagenesis:

  • Mutate predicted N-glycosylation sites (SERPINA11 has four predicted sites)

  • Express wild-type and mutant proteins in cell culture

  • Compare secretion efficiency, stability, and inhibitory activity

Understanding these modifications is crucial as they may regulate SERPINA11's inhibitory activity, tissue distribution, and half-life in circulation.

Why might Western blots show multiple bands or bands at unexpected molecular weights when using SERPINA11 antibodies?

Multiple bands or unexpected molecular weights when detecting SERPINA11 by Western blot may result from several biological and technical factors:

• Post-translational modifications:

  • Tissue-specific glycosylation patterns (observed in mouse brain, heart, and kidney)

  • Differential protein processing or cleavage

• Alternative splice variants: SERPINA11 may have tissue-specific isoforms

• Protein-protein interactions: Stable complexes with target proteases may appear as higher molecular weight bands

• Technical considerations:

  • Incomplete sample denaturation

  • Partial protein degradation during sample preparation

  • Non-specific antibody binding

To address these issues:

• Compare observed weights with the predicted molecular weight (approximately 47 kDa)

• Treat samples with deglycosylation enzymes to determine if higher molecular weight bands are due to glycosylation

• Use multiple antibodies targeting different epitopes to confirm band identity

• Include appropriate positive controls (recombinant SERPINA11) with known molecular weight

In mouse tissues, SERPINA11 has been detected at approximately 47 kDa in lung, liver, and testis, while higher molecular weight bands were observed in brain, heart, and kidney, suggesting tissue-specific post-translational modifications .

What factors might affect the detection sensitivity of SERPINA11 in different experimental contexts?

Several factors can influence SERPINA11 detection sensitivity:

• Antibody characteristics:

  • Epitope accessibility (antibodies targeting different regions may have varying efficacy)

  • Affinity and specificity of the antibody

  • Clonality (monoclonal vs. polyclonal)

• Sample preparation:

  • Buffer composition (consider protease inhibitors and detergents)

  • Protein denaturation conditions

  • Fixation methods for IHC/immunofluorescence (formalin fixation may mask epitopes)

• Biological variability:

  • Expression levels across tissues (highest in liver)

  • Developmental stage (expression patterns may change during development)

  • Disease state (e.g., downregulation in HCC)

• Technical parameters:

  • Antibody dilution (optimize between 1:500-1:5000 for WB)

  • Incubation time and temperature

  • Detection method sensitivity (chemiluminescence vs. fluorescence)

To optimize detection:

• Test multiple antibody concentrations

• Compare different antigen retrieval methods for IHC/immunofluorescence

• Consider signal amplification strategies for low-expression tissues

• Use positive control tissues with known high expression (liver)

How can researchers reconcile contradictory findings regarding SERPINA11 expression or function?

When facing contradictory results regarding SERPINA11, consider these methodological approaches to resolve discrepancies:

• Methodological differences:

  • Analyze detection methods (transcript vs. protein level measurements)

  • Compare antibody specifications (epitope locations, validation data)

  • Assess sample preparation protocols that might affect detection

• Biological variables:

  • Examine tissue source differences (developmental stage, disease state)

  • Consider species differences (human vs. mouse SERPINA11 share 75% sequence identity)

  • Analyze cell-type specific expression within heterogeneous tissues

• Data integration strategies:

  • Correlate RNA and protein expression data

  • Use multiple antibodies targeting different epitopes

  • Employ orthogonal techniques (mass spectrometry)

• Functional validation:

  • Perform gain-of-function and loss-of-function studies

  • Investigate specific molecular interactions with proposed partners

  • Analyze phenotypic outcomes in different model systems

For example, while Serpina11 transcript has been reported only in liver in adult mice, protein detection in multiple tissues suggests either SERPINA11 transport via circulation or low-level transcription in these tissues . This apparent contradiction can be resolved through careful analysis of protein vs. transcript detection methods and sensitivity.

How might SERPINA11 antibodies contribute to understanding its role in developmental processes?

Recent identification of a perinatal lethal phenotype associated with SERPINA11 deficiency opens important research avenues:

• Developmental expression mapping:

  • Use immunohistochemistry and immunofluorescence to track SERPINA11 expression throughout embryonic development

  • Compare expression patterns across different species to identify evolutionarily conserved functions

• Cell type-specific roles:

  • Apply single-cell techniques combining RNA sequencing with antibody-based protein detection

  • Identify cell populations responsible for SERPINA11 production vs. responsive to its activity

• Extracellular matrix organization:

  • Analyze extracellular matrix composition and structure in models with altered SERPINA11 expression

  • Investigate interactions between SERPINA11 and matrix components

• Target protease identification:

  • Use co-immunoprecipitation with SERPINA11 antibodies to identify interacting proteases

  • Compare protease activity in tissues with normal vs. reduced SERPINA11 expression

• Therapeutic development:

  • Explore recombinant SERPINA11 administration in disease models

  • Investigate targeted delivery of SERPINA11 to specific tissues during development

These approaches would help elucidate SERPINA11's critical role in embryonic development and potentially identify strategies to address SERPINA11-related disorders .

What experimental designs could elucidate the relationship between SERPINA11 and cancer beyond hepatocellular carcinoma?

While SERPINA11's tumor suppressive role has been documented in hepatocellular carcinoma , its function in other cancers remains to be determined:

• Expression profiling across cancer types:

  • Use tissue microarrays and SERPINA11 antibodies to screen multiple cancer types

  • Correlate expression with clinical outcomes and molecular subtypes

• Functional genomics approaches:

  • Perform CRISPR/Cas9-mediated knockout in cancer cell lines

  • Assess effects on proliferation, invasion, and metastatic capacity

• Mechanistic investigations:

  • Evaluate interaction with known cancer-associated proteases beyond uPA

  • Investigate effects on tumor microenvironment and extracellular matrix remodeling

• Animal models:

  • Generate tissue-specific SERPINA11 knockout mice to assess cancer susceptibility

  • Analyze tumor development and progression in these models

• Biomarker potential:

  • Evaluate circulating SERPINA11 levels in cancer patients vs. healthy controls

  • Assess correlation with disease stage, treatment response, and recurrence

Given SERPINA11's role in extracellular matrix homeostasis and its ability to inhibit metastasis in HCC , investigation of its function in cancers characterized by extensive matrix remodeling would be particularly valuable.

What novel techniques or approaches could advance our understanding of SERPINA11 function?

Emerging technologies offer promising approaches to further elucidate SERPINA11 biology:

• Structural biology techniques:

  • High-resolution structural analysis of SERPINA11, particularly its reactive center loop (RCL)

  • Structural studies of SERPINA11-protease complexes to understand inhibition mechanisms

• Proteomic approaches:

  • Proximity labeling techniques to identify the SERPINA11 interactome

  • Global protease activity profiling in models with altered SERPINA11 expression

• Advanced imaging methods:

  • Super-resolution microscopy to visualize SERPINA11 localization at subcellular resolution

  • Intravital imaging to track SERPINA11 dynamics in vivo

• Single-cell technologies:

  • Single-cell proteomics to map SERPINA11 expression and function at cellular resolution

  • Spatial transcriptomics combined with antibody-based detection to correlate SERPINA11 protein with local transcriptional programs

• Therapeutic modulation:

  • Development of small molecule modulators of SERPINA11 activity

  • Targeted delivery of recombinant SERPINA11 to specific tissues

These approaches could reveal SERPINA11's precise molecular mechanisms, target proteases, and potential therapeutic applications in conditions characterized by dysregulated protease activity or extracellular matrix disruption.